[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:management":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,72,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618338","cares--customized-aftercare-report-for-evaluated-skin-cancer-patients-100618338",false,"NCT07330323","CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients","Development and Evaluation of a Personalized Discharge Letter for Low-risk Skin Cancer Patients After Dermatological Screening.","CARES","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Low-risk skin cancer patients:\n\n  1. Negative personal history for melanoma\n  2. Less than 100 naevi\n  3. Less than 5 clinically atypical naevi\n  4. Maximum 1 BCC in history\n  5. Maximum 1 SCC, and at least 5 years ago\n  6. AK: treated and controlled with clinical response\n  7. M Bowen: treated and controlled with clinical response\n* Adult subjects (between 18 years of age and 80 years) at time of enrolment\n\nExclusion Criteria:\n\n* Presence of dermatological lesions requiring immediate treatment at the time of consultation.\n* History of solid organ transplantation (Organ Transplant Recipient, OTR).\n* Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).\n* Failure to meet one or more of the inclusion criteria.\n* Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.","ALL","18 Years","80 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits.\n\nThis project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts .\n\nThe personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.",[28,29,30],"Management","Low Risk","Skin Cancer",[32,33,34],"Skin cancer risk and management","personalized discharge letter","low-risk skin cancer patients","RECRUITING","2026-05-20",{"date":38,"type":39},"2026-05-22","ACTUAL",{"date":36,"type":39},{"date":42,"type":22},"2029-06",{"name":44,"class":45},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":70,"locationsCount":46},"100603611","role-of-mri-in-the-early-diagnosis-and-management-of-acute-stroke-and-its-impact-on-turnaround-time-in-emergency-settings-100603611","NCT07138768","Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time in Emergency Settings","The Role of MRI in the Early Diagnosis and Management of Acute Stroke and Its Impact on Turnaround Time (TAT) in Emergency Settings","Inclusion Criteria:\n\n* Age ≥18 years.\n* Both sexes.\n* Patients with acute stroke who are admitted to the emergency department.\n\nExclusion Criteria:\n\n* Contraindications to magnetic resonance imaging (MRI) or computed tomography (CT).\n* Symptoms strongly suggestive of subarachnoid hemorrhage.\n* Initiation of antithrombotic or thrombolytic treatment before the completion of both scans.\n* Inability to complete both scans in time to allow thrombolytic treatment within three h of the onset of symptoms.\n* Uncontrollable hypertension.\n* Pregnant or lactating women.",{"count":55,"type":22},136,"OBSERVATIONAL","This study aims to evaluate the role of stroke protocol in the early diagnosis and management of acute stroke and its effect on turnaround time (TAT) in emergency settings.",[59,60,28,61,62,63],"Magnetic Resonance Imaging","Diagnosis","Acute Stroke","Turnaround Time","Emergency Settings","2025-08-23",{"date":66,"type":39},"2025-08-26",{"date":64,"type":39},{"date":69,"type":22},"2026-12-01",{"name":71,"class":45},"Tanta University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":46},"100602613","original-denis-brawn-brace-versus-its-modification-for-management-of-relapsed-idiopathic-clubfoot-following-ponseti-casting-100602613","NCT07125794","Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting","The Original Denis Brawn Brace Versus Its Modification for Management of Relapsed Idiopathic Clubfoot Following Ponseti Casting: A Retrospective Study.","Inclusion Criteria:\n\n* Age from 2 to 5 years.\n* Both sexes.\n* Relapsed cases.\n* Patients with idiopathic clubfoot.\n\nExclusion Criteria:\n\n* Neurological or syndromic involvement.\n* Presenting with skin or soft-tissue lesions around the foot and ankle.\n* Inadequate documentation.\n* Soft-tissue surgery is needed (except tendo-achilles tenotomy).\n* Irregular plaster casting schedule.","2 Years","5 Years",{"count":82,"type":22},60,"This study aims to compare the effectiveness of the original Denis Brawn brace to its modification in managing relapsed idiopathic clubfoot in patients following Ponseti casting.",[85,86,28,87,88],"Denis Brawn Brace","Modification","Idiopathic Clubfoot","Ponseti Casting","2025-08-10",{"date":91,"type":39},"2025-08-15",{"date":93,"type":39},"2025-05-01",{"date":95,"type":22},"2026-05-01",{"name":97,"class":98},"The General Authority for Teaching Hospitals and Institutes","NETWORK",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":117,"locationsCount":46},"100580189","added-value-of-ultrasonography-in-the-diagnosis-management-and-follow-up-of-carpal-tunnel-syndrome-100580189","NCT06834061","Added Value of Ultrasonography in the Diagnosis, Management, and Follow-Up of Carpal Tunnel Syndrome","Inclusion Criteria:\n\n* Age ≥18 years old.\n* Both sexes.\n* Patients with carpal tunnel syndrome.\n\nExclusion Criteria:\n\n* History of wrist surgery (including carpal tunnel injection) or fracture.\n* Clinical or electrophysiological evidence of an accompanying condition that mimics carpal tunnel syndrome or interferes with its evaluation, such as proximal median neuropathy, cervical radiculopathy or polyneuropathy.\n* History of underlying disorders associated with carpal tunnel syndrome such as diabetes mellitus, rheumatoid arthritis, pregnancy, acromegaly or hypothyroidism.\n* Electrodiagnostic findings suggestive of co-existing neurological disorders.\n* Subclinical sensory polyneuropathy.",{"count":82,"type":22},"This study aims to assess the ultrasound (US) and nerve conduction studies (NCS) as a tool for diagnosis, treatment planning and follow-up of patients with carpal tunnel syndrome (CTS).",[108,60,28,109,110],"Ultrasonography","Follow-Up","Carpal Tunnel Syndrome","2025-02-19",{"date":113,"type":39},"2025-02-20",{"date":111,"type":39},{"date":116,"type":22},"2025-07-01",{"name":118,"class":45},"Kafrelsheikh University"]